<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">World J Gastroenterol</journal-id>
<journal-id journal-id-type="iso-abbrev">World J. Gastroenterol</journal-id>
<journal-id journal-id-type="publisher-id">WJG</journal-id>
<journal-title-group>
<journal-title>World Journal of Gastroenterology</journal-title>
</journal-title-group>
<issn pub-type="ppub">1007-9327</issn>
<issn pub-type="epub">2219-2840</issn>
<publisher>
<publisher-name>Baishideng Publishing Group Inc</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">26900286</article-id>
<article-id pub-id-type="pmc">4734998</article-id>
<article-id pub-id-type="other">jWJG.v22.i7.pg2219</article-id>
<article-id pub-id-type="doi">10.3748/wjg.v22.i7.2219</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Topic Highlight</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Gut microbiota role in irritable bowel syndrome: New therapeutic strategies</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Distrutti</surname>
<given-names>Eleonora</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Monaldi</surname>
<given-names>Lorenzo</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ricci</surname>
<given-names>Patrizia</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Fiorucci</surname>
<given-names>Stefano</given-names>
</name>
</contrib>
<aff>Eleonora Distrutti, Lorenzo Monaldi, S.C. di Gastroenterologia ed Epatologia, Azienda Ospedaliera di Perugia, 06100 Perugia, Italy</aff>
<aff>Patrizia Ricci, Stefano Fiorucci, Dipartimento di Scienze Chirurgiche e Biomediche, Università degli Studi di Perugia, 06100 Perugia, Italy</aff>
</contrib-group>
<author-notes>
<fn>
<p>Author contributions: Distrutti E, Monaldi L, Ricci P and Fiorucci S conceived and wrote the manuscript.</p>
<p>Correspondence to: Eleonora Distrutti, MD, S.C. di Gastroenterologia ed Epatologia, Azienda Ospedaliera di Perugia, 06100 Perugia, Italy. <email>eleonoradistrutti@katamail.com</email></p>
<p>Telephone: +39-75-5784357 Fax: +39-75-5858120</p>
</fn>
</author-notes>
<pub-date pub-type="ppub">
<day>21</day>
<month>2</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="epub">
<day>21</day>
<month>2</month>
<year>2016</year>
</pub-date>
<volume>22</volume>
<issue>7</issue>
<fpage>2219</fpage>
<lpage>2241</lpage>
<history>
<date date-type="received">
<day>28</day>
<month>5</month>
<year>2015</year>
</date>
<date date-type="rev-recd">
<day>5</day>
<month>12</month>
<year>2015</year>
</date>
<date date-type="accepted">
<day>30</day>
<month>12</month>
<year>2015</year>
</date>
</history>
<permissions>
<copyright-statement>©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.</copyright-statement>
<copyright-year>2016</copyright-year>
</permissions>
<abstract>
<p>In the last decade the impressive expansion of our knowledge of the vast microbial community that resides in the human intestine, the gut microbiota, has provided support to the concept that a disturbed intestinal ecology might promote development and maintenance of symptoms in irritable bowel syndrome (IBS). As a correlate, manipulation of gut microbiota represents a new strategy for the treatment of this multifactorial disease. A number of attempts have been made to modulate the gut bacterial composition, following the idea that expansion of bacterial species considered as beneficial (<italic>Lactobacilli</italic> and <italic>Bifidobacteria</italic>) associated with the reduction of those considered harmful (<italic>Clostridium</italic>, <italic>Escherichia coli</italic>, <italic>Salmonella</italic>, <italic>Shigella</italic> and <italic>Pseudomonas</italic>) should attenuate IBS symptoms. In this conceptual framework, probiotics appear an attractive option in terms of both efficacy and safety, while prebiotics, synbiotics and antibiotics still need confirmation. Fecal transplant is an old treatment translated from the cure of intestinal infective pathologies that has recently gained a new life as therapeutic option for those patients with a disturbed gut ecosystem, but data on IBS are scanty and randomized, placebo-controlled studies are required.</p>
</abstract>
<kwd-group>
<kwd>Irritable bowel syndrome</kwd>
<kwd>Gut microbiota</kwd>
<kwd>Probiotics</kwd>
<kwd>Prebiotics</kwd>
<kwd>Synbiotics</kwd>
<kwd>Antibiotics</kwd>
<kwd>Fecal transplantation</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>